Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

Clinical Immunology

Volumn 142, Issue 1, 2012, Pages 15-24

  Ingwersen, Jens ^a   Aktas, Orhan ^a   Kuery, Patrick ^a   Kieseier, Bernd ^a   Boyko, Alexey ^b   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Fingolimod; ; FTY720; ; Immunomodulation; Multiple sclerosis; ; Therapy;

Indexed keywords

DRUG METABOLITE; FINGOLIMOD; INTERFERON; NATALIZUMAB; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY TITER; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID; CLINICAL STUDY; COMMON COLD; CYTOKINE PRODUCTION; DEMYELINATION; DIABETES MELLITUS; DISABILITY; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENTEROCOLITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; JC VIRUS; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE MIGRATION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NEOPLASM; NERVE CELL DEGENERATION; NEURAL STEM CELL; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; RECURRENCE RISK; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINUSITIS; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84856209651     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.05.005     Document Type: Review

References (94)

1. Fujita T., Inoue K., Yamamoto S., Ikumoto T., Sasaki S., Toyama R., Chiba K., Hoshino Y., Okumoto T. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 1994, 47:208-215.
2. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009, 158:1173-1182.
3. Schwab S.R., Cyster J.G. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 2007, 8:1295-1301.
4. Foster C.A., Howard L.M., Schweitzer A., Persohn E., Hiestand P.C., Balatoni B., Reuschel R., Beerli C., Schwartz M., Billich A. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 2007, 323:469-475.
5. Miron V.E., Ludwin S.K., Darlington P.J., Jarjour A.A., Soliven B., Kennedy T.E., Antel J.P. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 2010, 176:2682-2694.
6. Choi J.W., Gardell S.E., Herr D.R., Rivera R., Lee C.W., Noguchi K., Teo S.T., Yung Y.C., Lu M., Kennedy G., Chun J. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:751-756.
7. Kim H.J., Miron V.E., Dukala D., Proia R.L., Ludwin S.K., Traka M., Antel J.P., Soliven B. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J. 2011, 25:1509-1518.
8. Fukushima N., Ishii I., Contos J.J., Weiner J.A., Chun J. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 2001, 41:507-534.
9. Gardell S.E., Dubin A.E., Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 2006, 12:65-75.
10. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 2003, 4:397-407.
11. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev. 2008, 60:181-195.
12. Dev K.K., Mullershausen F., Mattes H., Kuhn R.R., Bilbe G., Hoyer D., Mir A. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther. 2008, 117:77-93.
13. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., Choudhury S., Skerjanec A., Kraus G., Neumayer H.H. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 2002, 13:1073-1083.
14. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 1998, 160:5493-5499.
15. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., Foster C.A., Zollinger M., Lynch K.R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002, 277:21453-21457.
16. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
17. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
18. Mullershausen F., Zecri F., Cetin C., Billich A., Guerini D., Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol. 2009, 5:428-434.
19. Hla T., Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 2011, 76:S3-S8.
20. Beer M.S., Stanton J.A., Salim K., Rigby M., Heavens R.P., Smith D., Mcallister G. EDG receptors as a therapeutic target in the nervous system. Ann. N. Y. Acad. Sci. 2000, 905:118-131.
21. Teshima K., Imayoshi T., Matsura M., Yamaguchi S., Chiba K., Terasawa M. FTY720, a Novel Immunosuppressant, Possessing Unique Mechanisms. III. Pharmacological Activities in Several Autoimmune and Inflammatory Models. Abstracts of the 9th International Congress of Immunology, San Francisco 1995, 5172.
22. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
23. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005, 26:565-571.
24. Stromnes I.M., Goverman J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1:1810-1819.
25. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981, 11:195-199.
26. Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F. Neuronal damage in brain inflammation. Arch. Neurol. 2007, 64:185-189.
27. Ransohoff R.M. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol. 2006, 27:167-168.
28. Bartholomaus I., Kawakami N., Odoardi F., Schlager C., Miljkovic D., Ellwart J.W., Klinkert W.E., Flugel-Koch C., Issekutz T.B., Wekerle H., Flugel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
29. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005, 11:328-334.
30. Aktas O., Smorodchenko A., Brocke S., Infante-Duarte C., Schulze T.U., Vogt J., Prozorovski T., Meier S., Osmanova V., Pohl E., Bechmann I., Nitsch R., Zipp F. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005, 46:421-432.
31. Krishnamoorthy G., Saxena A., Mars L.T., Domingues H.S., Mentele R., Ben-Nun A., Lassmann H., Dornmair K., Kurschus F.C., Liblau R.S., Wekerle H. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 2009, 15:626-632.
32. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S., Li X.K. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003, 305:70-77.
33. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., Chiba K. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005, 2:439-448.
34. Webb M., Tham C.S., Lin F.F., Lariosa-Willingham K., Yu N., Hale J., Mandala S., Chun J., Rao T.S. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 2004, 153:108-121.
35. Balatoni B., Storch M.K., Swoboda E.M., Schonborn V., Koziel A., Lambrou G.N., Hiestand P.C., Weissert R., Foster C.A. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 2007, 74:307-316.
36. Papadopoulos D., Rundle J., Patel R., Marshall I., Stretton J., Eaton R., Richardson J.C., Gonzalez M.I., Philpott K.L., Reynolds R. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 2010, 88:346-359.
37. Rausch M., Hiestand P., Foster C.A., Baumann D.R., Cannet C., Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 2004, 20:16-24.
38. Foster C.A., Mechtcheriakova D., Storch M.K., Balatoni B., Howard L.M., Bornancin F., Wlachos A., Sobanov J., Kinnunen A., Baumruker T. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009, 19:254-266.
39. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 2008, 4:384-398.
40. + T-regulatory cells and enhances their functional activity. J. Immunol. 2005, 175:7973-7980.
41. + regulatory T cells. J. Immunol. 2007, 178:2458-2468.
42. + regulators. J. Immunol. 2008, 180:7636-7647.
43. Heng Y., Ma Y., Yin H., Duan L., Xiong P., Xu Y., Feng W., Fang M., Tan Z., Chen Y., Zheng F., Gong F. Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transpl. Int. 2010, 23:1259-1270.
44. +) T cells in vitro. Clin. Exp. Immunol. 2009, 157:40-47.
45. Commodaro A.G., Peron J.P., Lopes C.T., Arslanian C., Belfort R., Rizzo L.V., Bueno V. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest. Ophthalmol. Vis. Sci. 2010, 51:2568-2574.
46. +) T-regulatory cells in experimental autoimmune neuritis rats. Exp. Neurol. 2009, 216:75-82.
47. Jorns A., Rath K.J., Terbish T., Arndt T., Meyer Z.V., Wedekind D., Hedrich H.J., Lenzen S. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 2010, 151:3555-3565.
48. Wolf A.M., Eller K., Zeiser R., Durr C., Gerlach U.V., Sixt M., Markut L., Gastl G., Rosenkranz A.R., Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J. Immunol. 2009, 183:3751-3760.
49. Liu G., Burns S., Huang G., Boyd K., Proia R.L., Flavell R.A., Chi H. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 2009, 10:769-777.
50. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011, 69:759-777.
51. Miron V.E., Schubart A., Antel J.P. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274:13-17.
52. Miron V.E., Jung C.G., Kim H.J., Kennedy T.E., Soliven B., Antel J.P. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 2008, 63:61-71.
53. Van D.R., Van H.J., Verzijl D., Witte M., Ronken E., Van Het H.B., Lakeman K., Dijkstra C.D., Van D.V., Reijerkerk A., Alewijnse A.E., Peters S.L., De Vries H.E. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010, 58:1465-1476.
54. Coelho R.P., Payne S.G., Bittman R., Spiegel S., Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 2007, 323:626-635.
55. Jung C.G., Kim H.J., Miron V.E., Cook S., Kennedy T.E., Foster C.A., Antel J.P., Soliven B. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007, 55:1656-1667.
56. Miron V.E., Hall J.A., Kennedy T.E., Soliven B., Antel J.P. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 2008, 173:1143-1152.
57. Novgorodov A.S., El-Alwani M., Bielawski J., Obeid L.M., Gudz T.I. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 2007, 21:1503-1514.
58. Rau C.R., Hein K., Sattler M.B., Kretzschmar B., Hillgruber C., McRae B.L., Diem R., Bahr M. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. Am. J. Pathol. 2011, 178:1770-1781.
59. Osinde M., Mullershausen F., Dev K.K. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 2007, 52:1210-1218.
60. Rouach N., Pebay A., Meme W., Cordier J., Ezan P., Etienne E., Giaume C., Tence M. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur. J. Neurosci. 2006, 23:1453-1464.
61. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32:638-647.
62. Kremer D., Heinen A., Jadasz J., Gottle P., Zimmermann K., Zickler P., Jander S., Hartung H.P., Kury P. p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9087-9092.
63. Prozorovski T., Schulze-Topphoff U., Glumm R., Baumgart J., Schroter F., Ninnemann O., Siegert E., Bendix I., Brustle O., Nitsch R., Zipp F., Aktas O. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol. 2008, 10:385-394.
64. Mullershausen F., Craveiro L.M., Shin Y., Cortes-Cros M., Bassilana F., Osinde M., Wishart W.L., Guerini D., Thallmair M., Schwab M.E., Sivasankaran R., Seuwen K., Dev K.K. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J. Neurochem. 2007, 102:1151-1161.
65. Pebay A., Toutant M., Premont J., Calvo C.F., Venance L., Cordier J., Glowinski J., Tence M. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 2001, 13:2067-2076.
66. Edsall L.C., Pirianov G.G., Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J. Neurosci. 1997, 17:6952-6960.
67. Moore A.N., Kampfl A.W., Zhao X., Hayes R.L., Dash P.K. Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes. Neuroscience 1999, 94:405-415.
68. Postma F.R., Jalink K., Hengeveld T., Moolenaar W.H. Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: action through a specific cell surface receptor. EMBO J. 1996, 15:2388-2392.
69. Toman R.E., Payne S.G., Watterson K.R., Maceyka M., Lee N.H., Milstien S., Bigbee J.W., Spiegel S. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J. Cell Biol. 2004, 166:381-392.
70. Harada J., Foley M., Moskowitz M.A., Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 2004, 88:1026-1039.
71. Kimura A., Ohmori T., Ohkawa R., Madoiwa S., Mimuro J., Murakami T., Kobayashi E., Hoshino Y., Yatomi Y., Sakata Y. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007, 25:115-124.
72. Menn B., Garcia-Verdugo J.M., Yaschine C., Gonzalez-Perez O., Rowitch D., varez-Buylla A. Origin of oligodendrocytes in the subventricular zone of the adult brain. J. Neurosci. 2006, 26:7907-7918.
73. Picard-Riera N., Decker L., Delarasse C., Goude K., Nait-Oumesmar B., Liblau R., Pham-Dinh D., Evercooren A.B. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13211-13216.
74. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 2005, 25:11113-11121.
75. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 355:1124-1140.
76. Mehling M., Brinkmann V., Antel J., Bar-Or A., Goebels N., Vedrine C., Kristofic C., Kuhle J., Lindberg R.L., Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008, 71:1261-1267.
77. Mehling M., Hilbert P., Fritz S., Durovic B., Eichin D., Gasser O., Kuhle J., Klimkait T., Lindberg R.L., Kappos L., Hess C. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann. Neurol. 2011, 69:408-413.
78. Racke M.K. Understanding the effects of FTY720 on leukocyte trafficking. Arch. Neurol. 2010, 67:1433-1434.
79. + T cells in FTY720-treated patients with multiple sclerosis. Arch. Neurol. 2010, 67:1449-1455.
80. O'Connor P., Comi G., Montalban X., Antel J., Radue E.W., de V.A., Pohlmann H., Kappos L. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009, 72:73-79.
81. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de V.A., Jin J., Stites T., Wu S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
82. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
83. Hartung H.P., Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann. Neurol. 2009, 66:429-432.
84. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009, 8:28-31.
85. Johnson T.A., Shames I., Keezer M., Lapierre Y., Haegert D.G., Bar-Or A., Antel J. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol. 2010, 137:15-20.
86. Leypoldt F., Munchau A., Moeller F., Bester M., Gerloff C., Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009, 72:1022-1024.
87. Schwarz A., Korporal M., Hosch W., Max R., Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 2010, 74:2022-2024.
88. Kowarik M.C., Pellkofer H.L., Cepok S., Korn T., Kumpfel T., Buck D., Hohlfeld R., Berthele A., Hemmer B. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76:1214-1221.
89. Schmouder R., Serra D., Wang Y., Kovarik J.M., DiMarco J., Hunt T.L., Bastien M.C. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J. Clin. Pharmacol. 2006, 46:895-904.
90. Gergely P., Wallstrom E., Nuesslein-Hildesheim B., Bruns C., Zecri F., Cooke N., Traebert M., Tuntland T., Rosenberg M., Saltzman M. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult. Scler. 2009, 15:S125-S126.
91. Sanna M.G., Liao J., Jo E., Alfonso C., Ahn M.Y., Peterson M.S., Webb B., Lefebvre S., Chun J., Gray N., Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 2004, 279:13839-13848.
92. Kovarik J.M., Schmouder R.L., Hartmann S., Riviere G.J., Picard F., Voss B., Weiss M., Wagner F., Schmidt H.H. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J. Clin. Pharmacol. 2006, 46:149-156.
93. Hohlfeld R., Barkhof F., Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-S37.
94. Mehling M., Lindberg R., Raulf F., Kuhle J., Hess C., Kappos L., Brinkmann V. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75:403-410.